Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.
David F PensonAndrew J ArmstrongRaoul S ConcepcionArchana M AgarwalCarl A OlssonLawrence I KarshCurtis J DunsheeWilliam DugganQi ShenJennifer SuggGabriel P HaasCelestia S HiganoPublished in: Prostate cancer and prostatic diseases (2021)
ClinicalTrials.gov identifier NCT01664923.